Edwards Lifesciences (EW) PT Raised to $103 at Stifel

April 21, 2021 8:16 AM EDT
Get Alerts EW Hot Sheet
Price: $89.51 -0.98%

Rating Summary:
    21 Buy, 15 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 8 | New: 3
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $103.00 (from $100.00) while maintaining a Buy rating.

The analyst commented, "Overall, Edwards better-than-expected 1Q21 results marked a solid start to 2021, and post-release recovery trend/guidance commentary left us feeling encouraged about the set-up for the remainder of the year. Starting with 1Q21, sales/EPS both exceeded the upper-end of management guidance, with positive broad-based growth on a year-over-year and sequential basis, despite well-known, early-1Q COVID headwinds. Our strong sense from these results and management commentary is that a robust March drove the quarterly-beat. Encouragingly, first-time 2Q21 sales/EPS guidance ranges, exceeding prior Stifel/Street consensus at the low-end, suggest that positive late-1Q recovery trends have continued. Still, with only a couple of weeks/months of visible recovery, management seems to be taking a thoughtfully-conservative approach to guidance, re-affirming full-year top line ranges, and raising 2021 EPS by the 1Q beat. To the extent COVID recovery continues and vaccines are successfully rolled-out, we think guidance leaves room for positive upside/guidance revisions as the year unfolds."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities